Skip to main content
. Author manuscript; available in PMC: 2020 Nov 15.
Published in final edited form as: Vaccine. 2017 Sep 7;37(48):7190–7200. doi: 10.1016/j.vaccine.2017.08.058

Table 3.

Key Ebola vaccine characteristics and considerations for use.

Vaccine characteristics Considerations for use
Vaccine type Replication-competent viral vectors Appropriate for healthy adults and children, non-pregnant women
Non-replicating vectors and protein subunit vaccines Appropriate for the general population including immunocompromised and pregnant women
Species coverage Monovalent protection against Zaire ebolavirus Useful only for outbreak response to a known Zaire ebolavirus outbreak
Broad protection against Zaire ebolavirus, Sudan ebolavirus, and Bundibugyo ebolavirus Useful in multiple outbreak settings and for preemptive vaccination of international aid workers and healthcare/frontline workers in regions with multiple endemic species
Dosing regimen Single dose Ideal regimen for outbreak response
Primary dose plus booster dose(s) Difficult to implement as part of outbreak response where vaccinees may not be accessible or compliant for follow-up dose(s) Feasible for preemptive vaccination of
  • -

    Healthcare/frontline workers

  • -

    International responders

  • -

    Laboratory personnel involved in Ebolavirus research or routine testing
Durability of protection At least 3 months Useful for outbreak response
At least 1 year (ideally 3–5 years) Ideal for preemptive vaccination of
  • -

    Healthcare/frontline workers

  • -

    International responders

  • -

    Laboratory personnel involved in Ebolavirus research or routine testing

  • -

    Sexual contacts of survivors
Temperature stability Current experimental candidates:
  • -

    Storage requirement at −60 °C

  • -

    Stability at 2–8 °C for 27 days or less

  • -

    No vaccine vial monitor

 Feasible for
  • -

    Small scale outbreak response where research-level laboratory freezer (−80 °C) capacity and passive vaccine cold storage devices are available for transport of vaccine

  • -

    Preemptive vaccination in developed settings for aid workers, healthcare and laboratory personnel
Ideal candidates:
  • -

    Storage at −20 C

  • -

    Stability at 2–8 C for >6 months

  • -

    Not freeze-sensitive

  • -

    Vaccine vial monitor applied

 Best scenario for efficient vaccine delivery in all settings, especially endemic regions